Table 1. Antitumor Activity With Pembrolizumab in All Patients.
Best Overall Response | No. (%) [95% CI] (Nā=ā121) |
---|---|
Objective response rate (CR+PR) | 12 (9.9) [5.2-16.7]a |
Disease control rate (CR+PR+SD) | 37 (30.6) [22.5-39.6] |
CR | 0 [0-3] |
PR | 12 (9.9) [5.2-16.7] |
SD | 25 (20.7) [13.8-29.0] |
No assessmentb | 13 (10.7) [5.8-17.7] |
Progressive disease | 71 (58.7) [49.4-67.6] |
Time to response, median (range), mo | 4.1 (2.0-6.3) |
Duration of follow-up, median (range), moc | 13.3 (6.6-18.3) |
Duration of response, median (range), mo | Not reached (1.9-14.4) |
Abbreviations: CR, complete response; PR, partial response; SD, stable disease.
A total of 7 of 12 responses were ongoing at analysis.
No assessment includes patients who did not have a postbaseline tumor assessment as of the data cutoff date because the scans were missing or because the patient discontinued the study or died before the first postbaseline scan.
Median duration of follow-up in responders.